Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris
Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs.
micro-doses of Glucagon for Injection (Eli Lilly).